What records are connected here?
- Evidence lanes
- 2
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2Evidence: Smaller human trialsSkin
Melanotan II is a synthetic ring-shaped peptide of seven amino acids, recorded in FDA’s substance registry under the names Melanotan II and MT-II.1 Its human research is small and early: a 1996 pilot study in three men reported skin darkening and spontaneous erections, and a 2000 placebo-controlled study in 10 men with erectile dysfunction reported erections and nausea.6,7 FDA lists Melanotan II among compounding substances that may present significant safety risks, citing published case reports of serious adverse events including melanoma, a brain-swelling syndrome (PRES), a stimulant-like toxic reaction and priapism.2 No FDA approval is reported in the sources reviewed here, and Melanotan II is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
| What it is | A synthetic cyclic peptide, N-acetyl-norleucyl-aspartyl-histidyl-D-phenylalanyl-arginyl-tryptophyl-lysinamide closed into a ring between its second and seventh units, according to FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA lists Melanotan II among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2 |
| Human evidence | Two very small early studies, published in 1996 and 2000, one of them placebo-controlled, plus published case reports of serious adverse events cited by FDA.2,6,7 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Melanotan II is a synthetic peptide of seven units, N-acetyl-norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysinamide, with a bond closing the chain into a ring, according to FDA’s substance registry.1
The researchers who first tested it in people describe it as a ring-shaped analogue of alpha-melanocyte stimulating hormone (alpha-MSH) with very potent pigment-stimulating (melanotropic) activity in laboratory tests.6
As an analogue of alpha-MSH, it was studied for its effect on skin pigmentation, according to the 1996 pilot study.6
The authors of the 2000 study describe it as a synthetic melanotropic peptide that initiates erections. The FDA sources reviewed here do not describe its mechanism.2,7
In a 1996 pilot study, three healthy men received Melanotan II or saline on alternating days for two weeks. Two had increased pigmentation of the face, upper body and buttocks; mild nausea was common, one had marked sleepiness and fatigue, and spontaneous erections followed stretching and yawning.6
In a 2000 double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, erections were reported after 12 of 19 Melanotan II treatments and 1 of 21 placebo treatments. Nausea and stretching or yawning were more common with Melanotan II, and 4 of 19 treatments caused severe nausea.7
FDA cites published case reports that discuss serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome (a form of brain swelling), sympathomimetic toxidrome (a stimulant-like poisoning) and priapism (a prolonged, painful erection).2
These studies were very small and short, and the FDA sources reviewed here do not evaluate whether Melanotan II is effective for any use.2,6,7
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of Melanotan II by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.2
FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists Melanotan II among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.3,4
How often the serious adverse events in the case reports occur, since case reports cannot measure frequency or prove cause.2
Whether it is effective or safe for any condition: the two human studies reviewed here enrolled 13 men in total.6,7
What FDA’s advisory committee will conclude; its page did not give a meeting date.5
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Melanotan II: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Melanotan II are a bounded selection, not every registration or paper about Melanotan II. For the years before Melanotan II was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Melanotan II as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Melanotan II in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; on FDA’s compounding safety-risk list. Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; on FDA’s compounding safety-risk list. Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date March 7, 2026
CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.↗Source date March 7, 2026Literature metadata · added November 15, 2026
5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.↗Source date April 8, 2024Literature metadata · added November 15, 2026
Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.↗Source date February 15, 2022PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.
The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II.
PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
16 with attributed title, venue, publication-date, and type metadata.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 13, 2006 to March 7, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 35188390 in Journal of medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-21 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38285527 in Chemistry (Weinheim an der Bergstrasse, Germany) as Journal Article, with publication-date metadata of 2024-02-15 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 34464955 in Dermatology (Basel, Switzerland) as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19043625 in Beilstein journal of organic chemistry as Journal Article, with publication-date metadata of 2008-10-30 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 31953620 in CEN case reports as Case Reports, Journal Article, Review, with publication-date metadata of 2020-01-18 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32674774 in Analytica chimica acta as Journal Article, with publication-date metadata of 2020-05-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24771717 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2014-04-25 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 11035391 in International journal of impotence research as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 7981427 in Biopharmaceutics & drug disposition as Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-07 (month precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 26108334 in Alcoholism, clinical and experimental research as Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2015-06-24 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9106033 in Journal of chromatography. B, Biomedical sciences and applications as Journal Article, with publication-date metadata of 1997-03-07 (day precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 8637402 in Life sciences as Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug melanotan-ii. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
Life Sciences · Official source · Source checked November 16, 2026
Urology · Official source · Source checked November 16, 2026